CClinicalTrials.gg
RecruitingNCT05873023Updated May 24, 2023

Chewing Gum and Cognitive Function

An interventional study of Chewing gum in Cognitive Dysfunction, sponsored by Inha University Hospital. Recruiting at 4 sites in Korea, Republic of. Open to participants aged 60 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Inha University Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
60 Years to 79 Years
Sex
All
01

Study summary

This study is to investigate whether the improvement or maintenance of cognitive function is superior to the control group when gum chewing is performed in elderly people with subjective cognitive decline or mild cognitive impairment.

Read the detailed description

The intervention group chew one unscented gum provided by the study for 12 weeks. Using KakaoTalk, the coordinator sends a chewing gum alarm.

The participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side.

After chewing gum, they perform masticatory muscle stretching and tongue exercises. After they finish chewing the gum, he or she reports completion by posting an authentication photo in the KakaoTalk chat room.

The research coordinator checks the certification on a weekly basis and sends a separate phone call to encourage participants who do not chew gum more than twice a week.

02

Conditions studied

  • Cognitive Dysfunction
03

Who can participate

Ages eligible
60 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 60 to 79 years of age
  • All posterior teeth are evenly occluded on both sides, and those who have lost 4 or less teeth in the posterior teeth
  • Those who scored 50 points or less on the periodontal disease self-checklist
  • Meet the diagnostic criteria for subjective cognitive decline or mild cognitive impairment
  • Provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Those who have difficulty in chewing due to toothache, periodontal disease, temporomandibular joint disease, severe malocclusion, shaking teeth, etc.
  • Those who wear dentures on the upper or lower teeth
  • Dementia
  • Major psychiatric illness such as major depressive disorders
  • Other neurodegenerative disease (e.g., Parkinson's disease)
  • Other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease, or any medical conditions preventing to complete the study as judged by the study physician
  • Severe loss of vision, hearing, or communicative disability
  • Significant laboratory abnormality that may result in cognitive impairment
  • Any conditions preventing cooperation as judged by the study physician
  • Coincident participation in any other intervention trial
  • Those who are planning dental treatment such as preservation, prosthetics, and implants during the research period
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Intervention

    The intervention group chew one unscented gum provided by the study for 12 weeks. The participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side. After chewing gum, they perform masticatory muscle stretching and tongue exercises. After they finish chewing the gum, he or she reports completion by posting a proof photo in the KakaoTalk chat room.

    Other: Chewing gum

  • No intervention
    Control

    The control group does not participate in chewing gum.

Interventions

  • OtherChewing gum

    chewing gum everyday for 12 weeks. Alternate chewing for 10 minutes on the right and 10 minutes on the left.

05

What researchers measure

Primary outcomes

  1. Change of cognition

    Repeatable Battery for the Assessment of Neuropsychological Status (range 40-160). Higher scores indicate better performance.

    Time frame: Change from Baseline at 12 weeks

Secondary outcomes

  1. Change of global cognition

    Korean Mini-Mental State Examination-2 (range, 0-30). Higher scores indicate better performance.

    Time frame: Change from Baseline at 12 weeks

  2. Change of function

    Clinical Dementia Rating scale-Sum of Boxes (range 0-18). Higher scores indicate worse performance.

    Time frame: Change from Baseline at 12 weeks

  3. Change of depression

    Geriatric Depression Scale-15 items (range 0-15). Higher scores indicate worse mood.

    Time frame: Change from Baseline at 12 weeks

  4. Change of activities of daily living

    Bayer Activities of Daily Living (range 1-10). Higher scores indicate worse performance.

    Time frame: Change from Baseline at 12 weeks

  5. Change of quality of life

    Quality of life-Alzheimer's disease (range 0-52). Higher scores indicate better performance.

    Time frame: Change from Baseline at 12 weeks

Other outcomes

  1. Change of cortical thickness and brain network function

    brain MRI (3D-T1 weighted images and resting state functional MRI)

    Time frame: Change from Baseline at 12 weeks

06

Study locations

4 of 4 sites recruiting
  • Bobath Memorial Hospital
    Seongnam, Gyeonggi-do 13552, Korea, Republic of
    Recruiting
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
    • Seong Hye Choi, MD · Contact
    Recruiting
  • Ewha Womans Seoul Hospital
    Seoul, Korea, Republic of
    • Jee Hyang Jeong, MD, PhD · Contact
    Recruiting
  • Ajou University Hospital
    Suwon, Korea, Republic of
    • So Young Moon, MD, PhD · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — The data that support the findings of this study will be available from the principal investigator upon reasonable request.

Supporting information: Study protocol, Sap, Csr, Analytic code

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05873023
Lead sponsor
Inha University Hospital
Collaborators
Bobath Memorial Hospital
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Oct 17, 2022
Primary completion
Dec 15, 2023 (estimated)
Completion
Dec 29, 2023 (estimated)
Last update
May 24, 2023

Study contacts

Seong Hye Choi, MD, PhD
Contact
seonghye@inha.ac.kr
82 32 8902947
Hae Ri Na, MD, PhD
Contact
neuna102@paran.com
Hae Ri Na, MD, PhD
principal investigator · Bobath Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion